Results 171 to 180 of about 12,460 (212)
Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance [PDF]
International Journal of Infectious Diseases, 2020 Introduction: A possible increase in Candida resistance, especially in Candida glabrata, has been speculated according to poor diffusion of echinocandins to peritoneal fluid.
Francesca Gioia +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Echinocandins in Ocular Therapeutics
Journal of Ocular Pharmacology and Therapeutics, 2017Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash, Patil, Soumyajit, Majumdar
openaire +2 more sources
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem, Temesgen +2 more
openaire +2 more sources
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás, Emri +3 more
openaire +2 more sources
Update on Echinocandin Antifungals
Seminars in Respiratory and Critical Care Medicine, 2008Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Carol A, Kauffman, Peggy L, Carver
openaire +2 more sources
Echinocandins: Are They All The Same?
Journal of Chemotherapy, 2011The discovery of echinocandins, and their development and approval, was hailed as a significant addition to our antifungal armamentarium, previously predominated by polyenes and azoles. To date, three echinocandins (anidulafungin, caspofungin, and micafungin) have been approved by the U.S.
P K, Mukherjee +4 more
openaire +2 more sources
Echinocandins for the Nursery: An Update
Current Drug Metabolism, 2013As the incidence rates of neonatal invasive fungal infection (IFI) have been increasing over the last years, research efforts have been addressed towards identifying both effective preventative strategies, and efficacious and well-tolerated antifungal drugs.
Paolo, Manzoni +7 more
openaire +2 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Anidulafungin, a New Echinocandin
Drugs, 2009Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
G. Morace +3 more
openaire +6 more sources
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources